Allogeneic Cell Therapy Platform that Leverages Natural Platelet Biology PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges. biotechnology, platelets, and drug discovery

459 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pan Cancer T is a biotech company developing T cell receptor (TCR) T-cell therapy for solid tumours Pan Cancer T is a biotechnology spin-out (Erasmus MC, Rotterdam) focussed on the discovery and development of T cell receptor (TCR) T cell therapies. We exploit the 20 years of pioneering in adoptive T cell therapy as a springboard to breakthrough treatment of solid tumors. Pan Cancer T develops natural affinity TCR T cell therapies towards unique and proprietary intracellular targets expressed by multiple solid tumors, and make T cell therapy maximally accessible despite the tumor micro-environment challenges.

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy

344 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Leman Biotech, a spin-off company of EPFL, aims at developing and commercializing new metabolic cancer immunotherapies Leman Biotech is a clinical-stage cancer immunotherapy company co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and XtalPi, a leader in AI-driven drug research and development. The company integrates innovative metabolic reprogramming technology with a cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies. Leman Biotech's Metabolic Reprogramming Technology (Meta 10) represents an innovative approach to combating T-cell exhaustion. Preclinical studies have demonstrated its ability to activate oxidative phosphorylation metabolism in terminally exhausted T cells, restoring …

99 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. biotechnology, research, T cell, biologics, and science

211 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the full potential of cell therapies for patients around the world SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics. Our goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With accelerated production timelines under …

186 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Advancing Cancer Treatment Breakthroughs Carcinotech provides comprehensive solid tumor research services to advance drug development and enhance personalized therapy decisions. At the heart of its offerings is the proprietary Carcino3DTM bioprinting technology, which creates assay-ready, 3D tumors derived from patient biopsies. This innovative, translational approach delivers a predictive in vitro model, generating critical insights into therapeutic efficacy, and treatment optimization. Cancer research, 3D bioprinting , Cancer microenvironment, drug testing, oncology, assay services, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, early phase drug development, and early drug discovery

274 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. We have developed a pipeline of ‘off-the-shelf’ vaccines which induce immune responses and highly tumour specific monoclonal antibodies that redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and …

78 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Off-the-shelf precision vaccines to prevent deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival.

150 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our breakthroughs in immunology make Life Without Disease ® possible. La Jolla Institute for Immunology (LJI) Our breakthroughs in immunology make life without disease possible. We are a non-profit medical research institute dedicated to increasing knowledge and improving human health through studies of the immune system. We solely focus on the immune system because it holds the power to prevent, treat, and ultimately eliminate disease, extending healthy human life. At LJI, we accelerate lifesaving discoveries by combining a uniquely agile research environment with cutting-edge technology—empowering our world-class scientists to aim higher and move faster. What is immunology? Immunology is a …

59 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

INDIVIDUALIZED NK CELL THERAPIES XNK Therapeutics is a clinical-stage biotechnology company developing unique and individualized natural killer (NK) cell-based cancer therapies. The R&D pipeline targets areas of high unmet medical need within both hematological malignancies and solid tumors. The most advanced product candidate, evencaleucel, is being evaluated in a phase II clinical study in combination with the CD38 monoclonal antibody, isatuximab, as consolidation therapy following stem cell transplantation in newly diagnosed multiple myeloma patients. At the core of XNK is a committed and experienced team that includes world-renowned NK cell experts and pioneers in the field. The company has developed …

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Development of CAR-T cell based cancer therapies T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. CAR-T cells are a transformative, one-shot, chemotherapy-free targeted and personalized cancer treatment. T-CURX has exclusive licenses for proprietary technologies and CAR-T product opportunities developed in the laboratory of Prof. M. Hudecek, Würzburg, Germany one of the leading European clinical CAR-T cell laboratories. T-CURX leverages several cutting-edge CAR-T engineering technologies, including virus-free transposon based genetic engineering and a highly flexible and modular CAR format. This provides unparalleled flexibility, efficacy, safety, …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Leading the Next Frontier of Cell Therapy Sonoma Biotherapeutics is a South San Francisco and Seattle-based clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. Sonoma Bio has initiated two Phase 1 studies to evaluate the safety and proof-of-mechanism of the company’s lead Treg cell therapy candidate, SBT-77-7101, in patients with rheumatoid arthritis and hidradenitis suppurativa. …

129 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Antibody Targeted Biologics atbtherapeutics is a pioneering biopharmaceutical company building a new line of attack against cancer. atbtherapeutics has developed the atbody; a game-changer biologic format designed to broaden the therapeutic window of antibody-based therapies. Only our proprietary and versatile plant-based atbiofarm technology enables single-step manufacturing of our novel class of therapeutic atbodies. The resulting therapeutics offer a novel mechanism of action, avoiding major cancer cell resistance, and provide a promising, life-changing therapy for hard-to-treat and refractory cancer.

100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

125 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Revolutionizing Cell Therapy with Protein Design Outpace is creating cell therapies with curative potential through protein design and cellular engineering. With an initial focus on solid tumors, Outpace is developing technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLastTM), recruit a productive immune response in the tumor microenvironment (OutSmartTM), and achieve the potency (OutSpacersTM), specificity (Co-LOCKRTM), and safety (EGFRoptTM) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of …

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

‘Off-the-Shelf’ Curative Cell Therapies About Us: Cell BioEngines is a US-based clinical-stage biotechnology company developing off-the-shelf allogeneic cell therapies by chemically reprogramming stem cell fate and function to treat serious and currently incurable diseases. Leveraging cord blood stem cells from highly compatible 'super-donors' and powered by its proprietary STEM-Space cellular reprogramming platform, the company delivers scalable cell products with reduced risk of immune rejection. Cell BioEngines’ competitive edge comes from a unique combination of a transgene-free scalable manufacturing platform enabled by advanced chemical reprogramming, rigorous HLA-guided design, and a population-informed biobank that supports broad patient coverage. Cell BioEngines lead clinical …

311 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

260 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

ON DEMAND CYTOKINE Company Trutino means ‘Balance’ in Latin, and this represents our strategy, namely an Rx/Dx approach for Precision Oncology Drug & Clinical Development. The company logo symbolizes well balanced wings. As it takes both wings to fly, we believe a balanced Rx/Dx drug development will ultimately deliver on the promise of Precision Oncology. Our effort focuses on ‘targeted destruction of cancer cells’ and simultaneous ‘differential activation of tumor-specific immune cells’ to maximize treatment response. ON DEMAND CYTOKINE, CYTOKINE DRUG, IMMUNO-ONCOLOGY, and TARGETED ONCOLOGY

166 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing the next generation bacterial cancer therapy Developing the next generation bacterial cancer therapy The vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria. T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein …

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing next-generation immunotherapies for cancer patients! Kineta is a clinical stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Antivirals, Chronic Pain, Immuno-oncology, Biodefense, Immunology, Virology, Lassa fever, and Neuroscience

62 similar entities Type: Startup Activities: biotech deeptech

Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

372 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dark Genome-Derived Therapeutics Targeting Cellular Senescence in Cancer & Metabolic Disease Advancing immunotherapies targeting “dark genome” antigens, specifically HERV-K. Aberrant activation and expression of HERV-K in chronic inflammation, metabolic stress, cancer, and aging — drive immune evasion, senescence, and metabolic dysfunction and disease. By breaking immune tolerance to HERV-K, HERVolution is developing differentiated, off-the-shelf therapies that sit at the intersection of inflammation, type-2 diabetes disease, oncology, and longevity. Oncology, Aging, Dark Genome, ALS, Diabetes, Longevity, and Senescense

68 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells. LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. By decoding the language of the neuroimmune cross-talk, we are developing first-in-class therapeutic products – NRILs: neuronal reprogrammers of innate lymphocytes - to preserve health and treat inflammatory, infectious and metabolic diseases. We are bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

LIVING CURES Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Biotechnology, Vaccines, Oral delivery, Immunology, Synthetic Biology, Oncology, Microbial Immunotherapy, and Immunotherapy

101 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-PrimeTM, and novel drug candidates based on the RUBYTM bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator ́s technology platform comprises the proprietary technologies ALLIGATOR-GOLD® and FIND®. ALLIGATOR-GOLD® is a human antibody library containing more …

73 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

267 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

A cell-therapy technology company developing artificial membrane-binding proteins for oncology and regenerative medicine CytoSeek's mission is to use cell membrane augmentation technology to unlock the potential of next generation advanced therapies. Our novel cell membrane augmentation technology enables us to add new functionalities to various therapeutic cells. CytoSeek is engaged in proof of principle studies to demonstrate enhancement of cell therapies for cancer. We are looking to partner with cell therapy companies to bring these products to the clinic and ultimately enhance human health. Biochemistry, Immunology, Oncology, Regenerative Medicine, Cell therapies, and Proteins

121 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovation focused private biotech dedicated to delivering next-generation multispecific antibody therapeutics. F-star is a private biotech, based in Cambridge UK, focused on using our world-leading, innovative bispecific antibody technology that is clinically validated, patent protected and designed to create therapeutics that help more people with cancer and other serious diseases live longer with improved lives. bispecific antibodies, immuno-oncology, Immmunotherapy, oncology, cancer, tetravalent bispecifics, cancer research, biotech, immunology, CNS, and autoimmunity

101 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Going beyond treatment, striving for cures Cycuria Therapeutics is a preclinical-stage oncology startup based in Graz, Austria, founded by scientists from the Medical University of Graz, TU Munich and the University of Heidelberg. We are pioneering a novel protein-based targeted therapy for hematological cancers and beyond. Our approach selectively targets tumor and tumor stem cells while preserving healthy hematopoiesis and overall physiology. This enables durable efficacy without dose-limiting toxicity, as demonstrated in preclinical animal models and patient-derived disease models. By combining excellent tolerability with long-lasting efficacy, our novel therapeutic strategy aims to address significant unmet needs in cancer treatment, offering …

197 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases. Many diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.​ Our first-in-class small molecules are developed to control T cell activation by modulating antigen presentation, altering how cells appear to the immune system so it can recognize and target them correctly. Our oncology treatment (GRWD5769) is delivering promising Phase 1/2 data in patients with solid tumors, demonstrating a strong safety and tolerability profile, as well as generating meaningful clinical activity. Our autoimmunity treatment (GRWD0715) is progressing in a Phase 1/2 …

104 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Early cancer detection in blood AMADIX is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is extending people's lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear. Biotechnology, Cancer Diagnostics, Innovation, Personalized medicine, Blood test, and Biomarkers

95 similar entities Type: Startup Activities: biotech deeptech

Developing Breakthrough Cancer Immunotherapies Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. Cancer Immunotherapies, Phosphatases, Immuno-Oncology, Checkpoint inhibitors, CAR-T, and Solid tumours and Lymphomas

344 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Let's Build Better Cells Together At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQureTM gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping …

334 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

MImAbs is an innovative start-up specialized in immunotherapy. Our goal is to develop monoclonal antibodies in cancer and inflammatory diseases for third parties (academics, pharmacuetical companies, biotechnologies, etc.) Anticorps monoclonaux, Immuno-pharmacologie, Génération et bioproduction d'anticorps, and Génération d'immunoconjugués

227 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug

228 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

359 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Apmonia Therapeutics is a clinical-stage biotechnology company developing innovative peptide therapeutics designed to target the tumor microenvironment and improve outcomes for patients with solid tumors. Our approach focuses on overcoming one of oncology’s greatest challenges: the tumor microenvironment, a protective ecosystem that drives tumor growth, immune escape, and treatment resistance. Our lead candidate, TAX2, is a first-in-class peptide modulator of the TSP-1/CD47 pathway. Following strong preclinical results and CTA approval in Europe, TAX2 is entering Phase 1/2a clinical development in advanced solid tumors. immunologie and oncologie

116 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering thymus-empowered T-cell platform to fight cancer and infection Smart Immune is a clinical-stage French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to fully and rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies. The company aims to radically improve outcomes for patients in hematology and immune-oncology. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is in Phase I/II clinical trials in cancer patients with AML and ALL, in SCID in the EU and the US. Smart Immune is also developing therapies using gene-modified T …

86 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reexploring the Cancer Immunopeptidome Kahimmune Therapeutics is a cutting-edge biotech company focused on reexploring the cancer immunopeptidome to develop next-generation immuno-oncology therapies. Leveraging groundbreaking insights into the “dark genome”, Kahimmune identifies novel neoantigens to create innovative cancer vaccines designed for synergistic combination therapies. Spun off from Gustave Roussy and SATT Paris-Saclay, Kahimmune leverages KahinomicsTM, its proprietary neoantigen discovery platform, along with an exclusive IP portfolio. This integrated approach supports the creation of a robust pipeline targeting high‐burden cancers, including pancreatic and colorectal tumors. Backed by an experienced founding team and strategic partnerships, Kahimmune is committed to advancing bold immunotherapy innovations …

64 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Innovative medicines to address haemato-oncology related life-threatening and rare diseases ElsaLys Biotech is a specialty pharmaceutical company, part of the Mediolanum Farmaceutici Spa group, focused on innovative medicines to address haemato-oncology related life-threatening and rare diseases. Following strategic acquisitions and targeted developments, ElsaLys is establishing an immunotherapeutic portfolio focused on niche specialty pharmaceuticals to answer unmet medical needs. Our commitment is to offer essential drugs meeting Public Health needs. Founded in 2013, ElsaLys Biotech is located in the heart of the European cluster Lyon Biopole, in Lyon, France. Anticorps thérapeutiques, Anticorps monoclonaux, Therapeutic antibodies, Monoclonal antibodies, ophtalmologie, immune microenvironment, vascular …

86 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Sharp understanding of the hardest things At Sagacity Health, we discover new horizons in oncology by merging Agentic AI with Biotech to decode the secret world inside tumors - turning unseen ecosystems into the next frontier of precision therapeutics. Our main objective is to bridge groundbreaking science, clinical partnerships, and industrial-scale innovation to bring first-in-class therapies from lab to patient. This is not just drug development; it is a paradigm shift in how we fight cancer.

265 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

Basic and translational research on cancer, immunity, metabolism and chronic diseases, toward precision medicine. Basic and translational research on cancer, immunity, metabolism and chronic diseases, to make precision medicine a reality.

59 similar entities Type: SMB Activities: biotech deeptech

Tumor Activated Therapy: targeting Tumor Micro-Environment functional proteins to induce tumor self-destruction The heterogeneity of cancer cells constitutes a strong limitation for the treatment of solid cancers like pancreas and Breast TNBC. Shifting to a new paradigm, Seekyo, a pre-clinical biotech Co. overpowers this challenge by targeting specific functional proteins selectively produced within the Tumor Micro-Environment (TME). Seekyo’s lead compound SKY01 induces a selective tumor self-destruction: • Efficacy and safety validated in small and large animals (e.g. Dogs). • Unprecedented antitumor efficacy vs. Standards of Care • Efficient in several tumors (Pancreas, Triple Negative Breast Cancer, lung, colorectal...) • Low …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We are an immunology lab pursuing innovative ways to control cancer as well as inflammation in diseases and graft. UMR Right is a joint research unit affiliated to INSERM (National Institute of Health and Medical Research), EFS (French Blood Bank Institute) and the University of Franche-Comté. We develop basic, translational and clinical research programs to improve knowledge, diagnosis and treatments in the context of cancer immunity and immunotherapy (Team: TIMC), and organ and cell transplantation, inflammatory and autoimmune diseases (Team: ATI). Our main goals: - Characterize the pathogenic or protective immune responses involved in these diseases in order to identify …

64 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Next-Generation Precision Medicine Approaches PredictCan is the first individual-centric preclinical platform to reproduce human biological diversity in vitro, enabling a true population-level "trial-in-a-dish" approach to predict drug efficacy, identify toxicity, and understand interindividual variability before clinical trials begin. Precision Medicine, Clinical Trial in the Dish, Personalized Care, Patient-derived models, Early Diagnosis, Solid Tumors, Cancer, Drug Screening, Pharmaco-Ethnicity, Artificial Intelligence, and Preclinical models

206 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology A.I.

Nanoparticle-Based Radiopharmaceuticals for Targeted Radiation Delivery to Cancer Cells aKen Medical is a biotechnology company that encapsulates highly potent radioactive materials within stable nanoparticles serving as "guided missiles" that deliver targeted radiation straight to tumors while protecting healthy tissue. Our universal nanoparticle platform is designed to address a wide range of cancers, enabling real-time monitoring and advancing a theranostic approach that paves the way for precision medicine. Radiopharmaceuticals, Targeted therapy, Theranostics, Radiation Therapy, Alphatherapy, Nanotechnology, Cancer Therapy, Biotechnology, Radiotherapy, and Precision Medecine

127 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction.

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Smart Way to Immune Tolerance TolerogenixX vision is to innovate Immunosuppression with its newly developed MIC Cell Treatments. MIC Cell Treatment is a curative ATMP approach to achieve a sustained regulation of the immune system in Transplant - and Autoimmune Disease Patients. TolerogenixX has been able to generate strong pre-clinical as well as clinical data in the indications of Transplantation and Autoimmune Diseases e.g. SLE since its foundation in 2016.

69 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

Decoding immune dysfunction at scale Graph is a precision immunology techbio that leverages perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Graph believes that due to an incomplete understanding of complex immune-mediated diseases, millions of patients are left without adequate treatment options - and AI trained with complex disease data can solve this.

62 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

AI-guided Functional Precision Medicine PreCombTherapeutics AG is a privately held Swiss biotechcompany focused on in vitro cancer diagnostic to improve cancer management. It’s automated microtumor-based 3DTwinTM technology enables clinical institutions to integrate the technology on-site in the hospital. The test makes it possible to functionally evaluate multiple cancer drugs, drug combinations and drug concentrations directly on patient-derived micro-tumors to maximize treatment outcome. Oncology, Combination therapies, Biotechnology, 3D tissue culture, Precision medicine, Drug profiling, Healthcare, Cancer therapy, Medtech, Life science, AI, and Personalized oncology

174 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

Transforming blood care. For good. Lindis Blood Care GmbH is a MedTech company pioneering innovative antibody-based technologies to set new standards in blood transfusion. Our mission: enabling the safe removal of tumor and immune cells from blood – improving patient outcomes and redefining transfusion care. Oncology, MedTech, Patient Blood Management, CancerResearch, PatientSafety, and HealthcareInnovation

69 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

A Swedish listed biotechnology company Cantargia develops antibody based therapies against the target IL1RAP. The two clinical programs are nadunolimab in phase II development for treatment of cancer, and CAN10 in phase I development for autoimmune/inflammatory diseases.

68 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

Reprogramming the solid Tumor Micro-Environment to unlock the full potential of cancer immunotherapy Lever Bio's goal is to develop novel immunomodulatory antibody-based therapeutics to overcome resistance to current immunotherapies, paving the way for next-generation immunotherapies and innovative combination treatments. Lever Bio's compounds target components of the solid tumor microenvironment to foster anti-cancer immune response enhancing recruitment, activation and sustained function of cytotoxic T lymphocytes against solid tumors. Immuno-oncologia and Terapia Cellulare

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Redefining the cancer-immune synapse for novel immune checkpoint mechanisms Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. OBT’s proprietary OGAP® target discovery platform …

134 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Your partner in immunology projects! ImmunXperts a Q2 Solutions Company, your partner for what’s next in assay and biomarker development, advanced laboratory testing, and translational immunology. ImmunXperts brings an unrivaled ability to efficiently develop immunogenicity and immuno-oncology in vitro assays – to address both wanted and unwanted immunity for novel modalities. Immunogenicity Assessment, Immune Academy, Training, Consultancy, immuno-oncology, Cell Therapy, In vitro, assay development, Primary cells, Immunogenicity, and Immunology

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Beyond Inhibition. Reprogramming Cancer Control. Kazia Therapeutics Limited (NASDAQ: KZIA) is a clinical-stage oncology company focused on high-need cancers of the central nervous system and select aggressive solid tumors. Founded in 2016, the company is dedicated to advancing transformative therapies by harnessing next-generation science, disciplined development, and a commitment to clinical impact. Our mission is to redefine cancer treatment by moving beyond conventional pathway inhibition toward therapeutic reprogramming of cancer biology by targeting regulatory drivers of growth, immune escape, and relapse to deliver more durable outcomes for patients with the greatest unmet need.

82 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Now a part of Catalent Cell & Gene Therapy With deep experience in viral vector scale-up and production, Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies. When it acquired MaSTherCell, Catalent added expertise in autologous and allogeneic cell therapy development and manufacturing to position it as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent has a global cell and gene therapy network of dedicated, large-scale clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. …

60 similar entities Type: Startup Activities: deeptech manufacturing biotech Technologies: Synthetic Biology

Cancer profiling for precision oncology and early cancer detection iCellate develops and provides cancer profiling services for precision oncology. iCellate’s CellMate® is a next generation circulating tumor cell (CTC)-based platform for cancer cell detection and comprehensive biomarker analysis. GeneMate® is an analysis for hereditary cancer and gBRCA testing. Cancer Diagnostics, Circulating Tumor Cells (CTC), Liquid Biopsy, Next Generation Sequencing, CDx, Hereditary Cancer, Early Detection, Cancer, and Solid Tumors

81 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering therapies for oncogene-driven cancers Haptena is a biotech company founded in 2025 by Professors Chiara Ambrogio and Roberto Chiarle, with the goal of advancing next-generation immunotherapies for genetically defined cancers. Our mission is to bridge the precision of targeted therapies and the transformative potential of immune-based treatments to deliver more durable options for patients with some of the most challenging tumors.

241 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Altevax is developing a disruptive immunotherapy technology against cancer Altevax is a Phase 2 clinical-stage biotechnology company developing a pioneering melanin-based immunotherapy platform for cancer treatment. Its patented technology enhances antigen-specific T-cell immune responses and is compatible with a broad range of peptides, with potential to complement existing immuno-oncology approaches, including anti-PD-1 therapies. Altevax’s lead program targeting TERT in glioblastoma is currently in Phase 2 clinical development. The company collaborates with leading clinical institutions, including AP-HP, and is actively fundraising and exploring strategic partnerships to accelerate development. Cancer vaccines, immunotherapy, melanin, therapeutic vaccines, Peptidic vaccines, infectious diseases, CD8 Killer T …

219 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

First-in-class immunomodulatory peptides. Evora Biosciences develops novel immunomodulatory peptides with the aim to bring first-in-class treatments to patients in areas of high unmet need. immunodermatology, peptides, inflammatory diseases, respiratory diseases, inflammation, and immunomodulation

87 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Modulating T-regulatory cells to balance immunity Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

137 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We Empower Cells In Vivo to Fight Diseases. EsoBiotec is a biotechnology company developing innovative therapeutics to fight cancer. Our mission is to empower the human body to tackle cancer by bringing in vivo engineering of cells to patients. We aim to develop cost-effective and off-the-shelf therapeutics and providing state-of-the-art cell therapies to maximise accessibility. Our disruptive approach holds the potential to transform the current standard of cell and gene therapies for cancer treatment. Gene therapy, Biotechnology, Oncology, Cell therapy, Cancer, in vivo engineering, virology, and Immunology

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Harnessing the immune system to fight cancer Takis is a biotech dedicated to cancer research. Our primary objective is the development of innovative therapies based on the principle that our immune system can be “instructed” to recognize the tumor and reject it as a foreign entity. For this purpose, Takis offers cutting-edge technologies and works with the idea that new cancer treatment must be based on in-depth knowledge of tumour biology and the concept of personalized cancer therapy. Together with some of its partners, Takis is involved in the identification of new biomarkers and in the development of molecular diagnostic …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

First In Class Adoptive Cell Therapies to Cure Patients Carla Biotherapeutics is a Biotech company developing first-in-class adoptive cell therapies tailored to treat diseases with high unmet medical need with a first focus on aggressive life-threatening cancer. Carla Biotherapeutics is founded by a team of seasoned clinicians, cell therapy scientists and biotech professional in Besançon, France with access to a world-class and unique cell-therapy platform. Carla Biotherapeutics’ ambition is to build and develop a pipeline of immunotherapies based on a fully integrated cell therapy platform to discover ena develop adoptive cell therapies tailored to each indication.

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A lean biotech company aiming to develop revolutionary immune-based treatment for various cancers. Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to develop the next-generation of vaccines for cancer and infectious disease. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Empowering Personalized Immunotherapy to Treat Cancer Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy. Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients. Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique. By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has …

99 similar entities Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology

Safer, more effective ADCs and protein-drug-conjugates with GoldenSiteTM technology VALANX has built GoldenSite, a site-specific conjugation platform that places ADC payloads in structurally shielded positions on the antibody, delivering significantly reduced off-target interaction while preserving and enhancing efficacy. Using GoldenSite, we are developing a LIV-1 targeting, differentiated ADC intended to treat metastatic triple-negative-breast cancer. Bioconjugation, Site-specific conjugation, PEGylation, Biotechnology, Research and Development, ADCs, Novel format conjugates, Radioconjugates, Next generation bioconjugates , and Site-agnostic conjugation

87 similar entities Tags: H2020 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Invectys a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers Invectys, Inc. is a privately owned clinical-stage company, headquartered in Houston, Texas, which is developing a new generation of First-in-Class products for cancer patients. Invectys has two wholly owned subsidiaries, Invectys, SAS (Paris) which is focused on scientific research and innovation and Invectys USA, Inc. (Houston) which is directing the clinical development of the Company’s lead HLA-G product. Since 2010, Invectys has raised over $60 million in private funds to develop its two innovative platforms of immunotherapy products which target “universal” tumor antigens. oncology, immunotherapy, …

59 similar entities Type: Startup Activities: deeptech biotech

Break Boundaries. Ignite Change. IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio, in clinical trials, and additional pipeline candidates through preclinical development. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York. IO Biotech has an experienced management team within the immune-oncology field …

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unmask Cancer, Elicit Immune Response Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases. A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism responsible for suppressing the immune response. Our first generation of Glycosylation inhibitors aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors. Glyco Immuno Oncology

60 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Building a pipeline of immuno-therapies to fight against cancer and multiresistant pathogens ALPIONER Therapeutics is a biotech company developing new generation of immunotherapies against cancer and multi-resistant pathogens. Its aT3-plaform is leveraging a bacterial secretion system to inject high quantity of peptides or functional proteins, into the cytosol of the host cell. ALP-102 is a first-in-class vaccine candidate targeting Pa infections while ALP-201-neo is neoantigen-based personnalized cancer vaccine.

79 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic ImCheck Therapeutics an @Ipsen company designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. antibodies, immuno-oncology, Immune checkpoint Modulators, Auto-immunity, innate immunity, oncology, cancer, precision-based medicine, adaptative immunity, EVICTIONtrial, ICT01, and gamma-deltaTcells

246 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

#biopharma #biotech #drugdiscovery #GPCR #Immunooncology #inflammation Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and …

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing the weapons that we need to defeat cancer. HEPHAISTOS-Pharma is a biotechnology startup developing anti-tumor immunotherapies to revolutionize cancer treatments by increasing the effectiveness of monoclonal antibodies and enabling the treatment of incurable tumors. Oncology, immunotherapy, and cancer

59 similar entities Type: Startup Activities: biotech deeptech

Crossing the next frontier, to give you a fair chance to fight Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. Our novel candidates harness microbiome-associated innate immune regulatory mechanisms. Inflammatory Bowel Diseases, Live Biotherapeutics, Microbiome, Immunotherapies, Immuno-oncology, and Immuno-inflammation

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

senolytic ADC StarkAge Therapeutics is a biotechnology company based in Lille, France, pioneering first-in-class senolytic antibody–drug conjugates (ADCs) to address age-related diseases, with an initial focus on oncology. The company’s lead program, STX-1, is a first-in-class ADC targeting DPP4, a highly selective marker of cellular senescence and a relevant tumor-associated antigen. STX-1 is currently progressing toward IND-enabling studies. oncology, ADC, Antibody Drug Conjugate, Senescence, and Senolytic ADC

77 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣 Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of …

283 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase …

188 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A versatile immunotherapy for personalized cancer medicine Inovactis is developing an innovative treatment against cancer on the border between several ongoing revolutions: individualized medicine, immunotherapy and synthetic biology. immunotherapy and personalized medicine

82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

LinKinVax aims at creating a universal, safe, enduring, vaccines platform against multiple pathogens. We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology.

133 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient. French consortium to develop new experimental models of cancer in 9 cancer pathologies of interest (Lung, Pancreas, Breast, Liver, Ovary...) 3 major R&D axes: - Developing in vivo models and cell-based assays - Mimicking the human biology by humanizing the tumor microenvironment in mice - Studying the microbiota in cancer patients Oncology, Cancer research, Patient derived Xenograft, Cell lines, Ex vivo assays, Microbiota, Data mining , Translationnal medecine, Humanized mice, Biomarker, Research and Development, In vivo models, Ex vivo models, and Cancer

264 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Prolonging life and increasing life quality of cancer patients through innovative immunotherapies. Learn more. Elicera Therapeutics is a clinical stage cell and gene therapy company focusing on immunooncology. The company develops CAR T-cells against both solid and liquid tumors based on its proprietary technology platform, iTANK, for a parallell activation of an innate immune response against cancer. Elicera also develops next generation oncolytic viruses with three combined mode-of-actions, applicable for treatment of most cancers. Cell and gene therapy, immunooncology, CAR T-cells, Oncolytic viruses, and immunotherapy

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

565 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Ready-to-use cell bank, for research, for patients Lymphobank - ready-to-use cell bank, for research, for patients. Lymphobank is a biotech company specializing in the supply of adult and placental blood cells for research use, the characteristics of which will be available online (www.lymphobank.fr), making it possible to choose the cellular product based on a donor of interest. Our services are focused on the development of cellular immunotherapy products. Furthermore, Lymphobank is developing an innovative allogeneic adoptive immunotherapy approach for hepatocellular carcinoma (the most common liver cancer and second cause of cancer death in the world, with nearly 750,000 deaths per …

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pushing the frontier by pioneering next-generation engineered T cell receptor therapies for solid cancers Neogene Therapeutics is a global, clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers. With offices in Santa Monica, CA and Amsterdam, the Netherlands, Neogene is aiming to change the paradigm of treatment for solid cancers. Neogene is a member of the AstraZeneca Group.

60 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

BIOMUNEX is a biopharmaceutical company focused on the discovery and development of breakthrough immunotherapeutics BIOMUNEX Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough immunotherapies using its Unique BiXAb® technology to create next generation bi- and multi-specific antibodies. Our disruptive biological approaches target a number of cancer types, in particular where there are unmet medical needs. We are committed to provide oncologists and patients with immunotherapies that are novel, efficacious and prolong life expectancy.

67 similar entities Type: Startup Activities: deeptech biotech

Targeting calcium signaling to cure auto-immune diseases KALSIOM is a biotech company founded in April 2020 and based in Brest, France, discovering and developing first-in-class therapies to treat auto-immunes disorders (AID) involving B-cell dysfunction with a high medical need. The company is focusing on developing first-in-class monoclonal antibodies modulating calcium-signaling pathways in lymphocytes. Immunology and Therapeutic antibodies

97 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Deep Immune Phenotyping & MultiOmics DataScience, for immune precision medicine Parean Biotechnologies is a next generation service company dedicated to advancing preclinical and clinical programs in the field of oncology and immune related diseases. Our comprehensive approach integrates an in-house wet lab (cytometry, cell sorting, libraries generation in bulk or single cell protocols) and a omics biostatistics unit to drive innovation and foster transformative breakthroughs. Key offerings includes: -Wet Labs: unparalleled proficiency in deep immune phenotyping and tumor cells, with a focus on T-Cell, B-Cell, NK, and other immune cell subsets. - End-to-End Immune Cells Analysis: comprehensive immune cells analysis …

72 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics

Unlocking in vivo cell therapy with the next generation of gene editing technology Brink Therapeutics is developing next-generation recombinases — ultra-precise and efficient enzymes that surpass CRISPR-Cas9. We aim to revolutionize Cell and Gene therapies, enabling large-scale production to treat cancer, genetic disorders, and other diseases.

105 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Next-generation, engineered monocyte immunotherapy for treating cancer Signadori Bio, is a preclinical-stage biopharmaceutical company developing a next generation, off-the shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumours. Founded by Dr Jean-Luc Perfettini and Professor Nathalie Chaput, and based on research conducted at Gustave Roussy, Signadori’s approach aims to overcome the challenges of the tumour microenvironment by harnessing the immune potential of gene-modified monocytes. Signadori is based in Paris and backed by Sofinnova Partners (Paris) and InVivo Partners (Barcelona). Immuno-Oncology and In-vivo Engineered Monocytes

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing allogeneic TCR-NK therapies for solid tumors Zelluna is pioneering allogeneic ‘off-the-shelf’ T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of solid cancers. The company’s platform combines the innate killing power of NK cells with precise solid tumour targeting of TCRs, designed to address the limitations of current cell therapies in solid tumours. The company’s lead candidate, ZI-MA4-1, is the worlds-first MAGE-A4 targeting TCR-NK therapy expected to enter clinical trials in 2026 For more info please visit www.zelluna.com Cancer treatment, Immunotherapy, Adoptive cell therapy, T cell receptor technologies, Immunooncology, and Solid tumors

293 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Improving cancer outcomes by overcoming hypoxia. StimOxyGen is a proprietary and world-leading innovative approach to address the global challenge of tumour hypoxia. Hypoxia, or lack of oxygen, is a common characteristic of solid tumours that contributes to the failure of many types of cancer treatment, particularly radiotherapy which relies on oxygen for maximum efficacy. We can solve this longstanding major unmet clinical need by fueling tumours with oxygen to maximise therapeutic effects of radiotherapy. nanotechnology, cancer research, hypoxia, and pancreatic cancer

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Based in Paris and in the USA, TheraVectys is an immunotherapy company spun off from the Institut Pasteur created in 2005 by Dr. Pierre Charneau. TheraVectys is pioneering the application of novel lentiviral vector technology to address most of unmet and critical medical needs. By creating the only Joint-Laboratory between a private company and the Institut Pasteur in Paris, TheraVectys develops an extensive pipeline of vaccine candidates to drive the widespread treatment and prevention of cancer and infectious diseases. Leveraging our proprietary technology platform, and the extensive virology expertise of the Institut Pasteur, TheraVectys provides a robust and highly effective …

61 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

A novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) PDC*line Pharma is a clinical-stage Biotechnology company that develops a new class of potent, off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line). Based on a robust preclinical package and a first-in-human phase Ib in melanoma, PDC*line Pharma reported promising Phase I/II results in lung cancer (PDC*lung) in 2024. Preparations are now underway for a randomized Phase II trial in lung cancer, and a Phase Ib trial in colorectal cancer with neoantigens (PDC*neo). The company has raised €61M …

118 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Next-Generation T cells for solid tumor patients Captain T Cell develops first-in-class, efficacy-enhanced T cell therapies against solid tumors that are not addressed by existing treatments. Captain T Cell generates next-generation TCR-T cells with enhanced persistence and the capacity to cope with the hostile tumor microenvironment of difficult-to-treat solid tumors. In addition, the company has established a novel allogeneic platform to enable off-the-shelf treatments of solid tumors. Captain T Cell is based in Schoenefeld/Berlin, Germany, and backed by leading European investors i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H. Captain T Cell was founded by a dedicated …

59 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Re-arming the innate immune system against solid tumours LIFT BioSciences is pioneering a new class of immunotherapy for hard-to-treat cancers based on allogeneic Immuno-Modulatory Alpha Neutrophils (IMANs)®. Our proprietary, platform harnesses neutrophils’ innate tumour-homing and infiltrating attributes, combined with their ability to directly kill cancer cells and safely orchestrate broader immune responses, offering a powerful and antigen-independent treatment option to overcome cancer resistance mechanisms, like suppressive tumour environment and immune evasion. Backed by deep neutrophil biology expertise and a scalable manufacturing platform, LIFT is advancing a differentiated pipeline with application across multiple solid cancers. oncology, cell therapy, solid tumours, first-in-class, …

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering therapies based on aptamer technology aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept. Biopharmaceutical, Biotechnology, Aptamers, Immunology, Stroke, and Inflammatory diseases

390 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Creating transformative medicines for patients with cancer Cytovation is a clinical stage immuno-oncology biotech developing first-in-class immunotherapies. CY-101, its lead asset, is a synthetic peptide engineered to selectively target tumor cells. CY-101 has a unique dual MoA applicable across solid tumors: (1) direct tumor-specific membrane lysis and in-situ vaccination, combined with (2) immune activation through inhibition of the β-catenin pathway. Building on strong FIH clinical data, Cytovation is advancing CY-101 to POC/pivotal clinical development with a focus on b-catenin-driven cancers. Biotech, Oncology, and Immuno-oncology

82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology